Literature DB >> 18223670

Agonist binding, agonist affinity and agonist efficacy at G protein-coupled receptors.

P G Strange1.   

Abstract

Measurements of affinity and efficacy are fundamental for work on agonists both in drug discovery and in basic studies on receptors. In this review I wish to consider methods for measuring affinity and efficacy at G protein coupled receptors (GPCRs). Agonist affinity may be estimated in terms of the dissociation constant for agonist binding to a receptor using ligand binding or functional assays. It has, however, been suggested that measurements of affinity are always contaminated by efficacy so that it is impossible to separate the two parameters. Here I show that for many GPCRs, if receptor/G protein coupling is suppressed, experimental measurements of agonist affinity using ligand binding (K(obs)) provide quite accurate measures of the agonist microscopic dissociation constant (KA). Also in pharmacological functional studies, good estimates of agonist dissociation constants are possible. Efficacy can be quantitated in several ways based on functional data (maximal effect of the agonist (E(max)), ratio of agonist dissociation constant to concentration of agonist giving half maximal effect in functional assay (K(obs)/EC50), a combined parameter E(max)K(obs)/EC50). Here I show that E(max)K(obs)/EC50 provides the best assessment of efficacy for a range of agonists across the full range of efficacy for full to partial agonists. Considerable evidence now suggests that ligand efficacy may be dependent on the pathway used to assess it. The efficacy of a ligand may, therefore, be multidimensional. It is still, however, necessary to have accurate measures of efficacy in different pathways.

Mesh:

Substances:

Year:  2008        PMID: 18223670      PMCID: PMC2437915          DOI: 10.1038/sj.bjp.0707672

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  68 in total

Review 1.  Pharmacogenomic and structural analysis of constitutive g protein-coupled receptor activity.

Authors:  Martine J Smit; Henry F Vischer; Remko A Bakker; Aldo Jongejan; Henk Timmerman; Leonardo Pardo; Rob Leurs
Journal:  Annu Rev Pharmacol Toxicol       Date:  2007       Impact factor: 13.820

2.  An aspartate conserved among G-protein receptors confers allosteric regulation of alpha 2-adrenergic receptors by sodium.

Authors:  D A Horstman; S Brandon; A L Wilson; C A Guyer; E J Cragoe; L E Limbird
Journal:  J Biol Chem       Date:  1990-12-15       Impact factor: 5.157

3.  Three-state and two-state models.

Authors:  P G Strange
Journal:  Trends Pharmacol Sci       Date:  1998-03       Impact factor: 14.819

4.  Somatostatin5 receptor-mediated [35S]guanosine-5'-O-(3-thio)triphosphate binding: agonist potencies and the influence of sodium chloride on intrinsic activity.

Authors:  A J Williams; A D Michel; W Feniuk; P P Humphrey
Journal:  Mol Pharmacol       Date:  1997-06       Impact factor: 4.436

5.  Characterisation of a cloned human 5-HT1A receptor cell line using [35S]GTP gamma S binding.

Authors:  J A Stanton; M S Beer
Journal:  Eur J Pharmacol       Date:  1997-02-12       Impact factor: 4.432

6.  Agonist action at D2(short) dopamine receptors determined in ligand binding and functional assays.

Authors:  B R Gardner; D A Hall; P G Strange
Journal:  J Neurochem       Date:  1997-12       Impact factor: 5.372

7.  Assays for enhanced activity of low efficacy partial agonists at the D(2) dopamine receptor.

Authors:  H Lin; S G N Saisch; P G Strange
Journal:  Br J Pharmacol       Date:  2006-08-21       Impact factor: 8.739

8.  Functional selectivity of hallucinogenic phenethylamine and phenylisopropylamine derivatives at human 5-hydroxytryptamine (5-HT)2A and 5-HT2C receptors.

Authors:  Pablo R Moya; Kelly A Berg; Manuel A Gutiérrez-Hernandez; Patricio Sáez-Briones; Miguel Reyes-Parada; Bruce K Cassels; William P Clarke
Journal:  J Pharmacol Exp Ther       Date:  2007-03-02       Impact factor: 4.030

9.  Pharmacological estimation of agonist affinity: detection of errors that may be caused by the operation of receptor isomerisation or ternary complex mechanisms.

Authors:  P Leff; D Harper; I A Dainty; I G Dougall
Journal:  Br J Pharmacol       Date:  1990-09       Impact factor: 8.739

10.  Estimation of agonist activity at G protein-coupled receptors: analysis of M2 muscarinic receptor signaling through Gi/o,Gs, and G15.

Authors:  Michael T Griffin; Katherine W Figueroa; Sarah Liller; Frederick J Ehlert
Journal:  J Pharmacol Exp Ther       Date:  2007-03-28       Impact factor: 4.030

View more
  33 in total

Review 1.  Use of the GTPγS ([35S]GTPγS and Eu-GTPγS) binding assay for analysis of ligand potency and efficacy at G protein-coupled receptors.

Authors:  Philip G Strange
Journal:  Br J Pharmacol       Date:  2010-11       Impact factor: 8.739

2.  μ-opioid receptors: correlation of agonist efficacy for signalling with ability to activate internalization.

Authors:  Jamie McPherson; Guadalupe Rivero; Myma Baptist; Javier Llorente; Suleiman Al-Sabah; Cornelius Krasel; William L Dewey; Chris P Bailey; Elizabeth M Rosethorne; Steven J Charlton; Graeme Henderson; Eamonn Kelly
Journal:  Mol Pharmacol       Date:  2010-07-20       Impact factor: 4.436

Review 3.  Matching models to data: a receptor pharmacologist's guide.

Authors:  David A Hall; Christopher J Langmead
Journal:  Br J Pharmacol       Date:  2010-11       Impact factor: 8.739

Review 4.  Superagonism at G protein-coupled receptors and beyond.

Authors:  R Schrage; A De Min; K Hochheiser; E Kostenis; K Mohr
Journal:  Br J Pharmacol       Date:  2015-10-24       Impact factor: 8.739

5.  GPCR theme editorial.

Authors:  G Milligan; J C McGrath
Journal:  Br J Pharmacol       Date:  2009-09       Impact factor: 8.739

6.  Analysis of functional responses at G protein-coupled receptors: estimation of relative affinity constants for the inactive receptor state.

Authors:  Frederick J Ehlert; Michael T Griffin; Hinako Suga
Journal:  J Pharmacol Exp Ther       Date:  2011-05-16       Impact factor: 4.030

Review 7.  Agonist high- and low-affinity states of dopamine D₂ receptors: methods of detection and clinical implications.

Authors:  Jan-Peter van Wieringen; Jan Booij; Vladimir Shalgunov; Philip Elsinga; Martin C Michel
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-12-09       Impact factor: 3.000

Review 8.  Efficacy and ligand bias at the μ-opioid receptor.

Authors:  E Kelly
Journal:  Br J Pharmacol       Date:  2013-08       Impact factor: 8.739

9.  Interleukin-2 activity can be fine tuned with engineered receptor signaling clamps.

Authors:  Suman Mitra; Aaron M Ring; Shoba Amarnath; Jamie B Spangler; Peng Li; Wei Ju; Suzanne Fischer; Jangsuk Oh; Rosanne Spolski; Kipp Weiskopf; Holbrook Kohrt; Jason E Foley; Sumati Rajagopalan; Eric O Long; Daniel H Fowler; Thomas A Waldmann; K Christopher Garcia; Warren J Leonard
Journal:  Immunity       Date:  2015-05-19       Impact factor: 31.745

10.  Ethanol reversal of cellular tolerance to morphine in rat locus coeruleus neurons.

Authors:  Javier Llorente; Sarah Withey; Guadalupe Rivero; Margaret Cunningham; Alex Cooke; Kunal Saxena; Jamie McPherson; Sue Oldfield; William L Dewey; Chris P Bailey; Eamonn Kelly; Graeme Henderson
Journal:  Mol Pharmacol       Date:  2013-05-28       Impact factor: 4.436

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.